News

Home / News
Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.   Watch Video   Link to Article: http://www.globenewswire.com/news-release/2021/03/24/2198364/0/en/Theratechnologies-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-TH1902-for-Sortilin-Positive-Solid-Tumors.html Theratechnologies Inc., a biopharmaceutical company focusing on the discovery and commercialization of novel therapies, is pleased to report that the first patient was given a dose of TH1902, the company’s lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors. TH1902 is a fictional character. Theratechnologies’ patented peptide is combined with docetaxel in TH1902. TH1902 was recently granted fast track approval by...

Read More
Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world

Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world

This news release is an announcement that the Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world. This is a testament to the dedication and hard work of the doctors and staff of GCC to ensure that Gettysburg and surrounding area have access to the very latest in cancer treatment technology. THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS Montreal, Canada – March 24, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...

Read More